Kezar’s Lead Asset Bounces Back With Lupus Win
Following Myositis Setback
Executive Summary
Kezar’s lead asset zetomipzomib has demonstrated clinical significance in a mid-stage lupus trial just weeks after a disappointment in myositis but more robust data are needed for the first-in-class selective immunoproteasome inhibitor.
You may also be interested in...
Kezar Puts All Its Eggs In One Basket
The group is instituting swingeing cuts to allow it to get to a mid-stage readout for zetomipzomib in lupus nephritis. What if the trial fails?
Asia Deal Watch: Inventiva Finds Japan/Korea Partner For Phase III NASH Candidate In Hepalys
Plus deals involving SK pharmteco/CBM, Kezar/Everest, Cerecin/University of Alberta, PeptiDream/Genentech, Aclipse/Chong Kun Dang and Cure Genetics/Frametact.